SMO and glioma: Moreover, we found that, in response to SMO agonist purmorphamine treatment, the activity of GLI1 was only slightly increased in SW 1088 glioma cells, which displays low NUSAP1 expression, but significantly increased in U-87 MG glioma cells, which exhibits high NUSAP1 expression.